Completed PHASE1 INTERVENTIONAL 1-arm NCT00995137

Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia

Pilot Study of Genetically Modified Haploidentical Natural Killer Cell Infusions for B-Lineage Acute Lymphoblastic Leukemia

Sponsor: Assisi Foundation

Conditions Lymphoblastic Leukemia, Acute

Interventions NK Cell Infusion

Updated 6 times since 2017 Last updated: Apr 24, 2017 Started: Oct 31, 2009 Primary completion: May 31, 2013 Completion: May 31, 2014

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Lymphoblastic Leukemia, Acute, this trial is completed. The trial is conducted by Assisi Foundation and has accumulated 6 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Oct 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Assisi Foundation
National Cancer Institute (NCI)
St. Jude Children's Research Hospital

Data source: St. Jude Children's Research Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Memphis, United States